<DOC>
	<DOC>NCT01818947</DOC>
	<brief_summary>The purpose of this study is to understand real world gefitinib usage patterns, patient characteristics and outcomes and to present these for a Caucasian population</brief_summary>
	<brief_title>Gefitinib Usage and Outcomes in Routine Treatment</brief_title>
	<detailed_description>A multicentre, retrospective chart review study to characterise gefitinib usage and outcomes in routine treatment</detailed_description>
	<mesh_term>Gefitinib</mesh_term>
	<criteria>Patients who received gefitinib first line in the UK Single Payment Access (SPA) scheme Locally advanced or metastatic EGFR mutation positive NSCLC Supplied with first pack of gefitinib prior to 1st January 2012 Patient was treated privately (i.e. outside the NHS) Gefitinib was secondline therapy following treatment failure on a prior therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Lung cancer</keyword>
	<keyword>epidermal growth factor receptor mutation</keyword>
	<keyword>gefitinib</keyword>
	<keyword>Iressa</keyword>
</DOC>